Investigational drug · Phase 3
Sigvotatug Vedotin
Also called: SGN-B6A, PF-08046047
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "Sigvotatug Vedotin"
First trial start
2024
Feb 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sigvotatug Vedotin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Advanced/Metastatic Non-Small Cell Lung Cancer
- Carcinoma, Non-Small Cell Lung
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Sigvotatug Vedotin" as an intervention, largest first.
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT04389632 · 1,006 participants (planned) · Start Jun 8, 2020 · Primary completion Jun 16, 2027
Drug: sigvotatug vedotin; pembrolizumab and 2 more · For: Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; HER2 Negative Breast Neoplasms and 9 more
Sites: Anchorage, Alaska; Fayetteville, Arkansas; Rogers, Arkansas · 158 sites in all
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerPivotal-lookingActive, not recruiting
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT06012435 · 762 participants · Start Feb 21, 2024 · Primary completion May 18, 2026
Drug: sigvotatug vedotin; docetaxel · For: Carcinoma, Non-Small-Cell Lung
Sites: Anchorage, Alaska; Fullerton, California; Los Alamitos, California · 331 sites in all
- This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06758401 · 714 participants (planned) · Start Jul 23, 2025 · Primary completion Sep 5, 2028
Drug: Sigvotatug Vedotin; Pembrolizumab · For: Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-Small-Cell Lung (NSCLC)
Sites: Fairbanks, Alaska; Fullerton, California; Golden, Colorado · 392 sites in all
PfizerPfizer (PFE)
NCT07227298 · 162 participants (planned) · Start Jan 30, 2026 · Primary completion Mar 8, 2029
Drug: PF-08634404; Sigvotatug Vedotin and 1 more · For: Advanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 108 sites in all
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT06549816 · 6 participants · Start Aug 21, 2024 · Primary completion Nov 18, 2025
Drug: sigvotatug vedotin · For: Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma and 3 more
Sites: Guangzhou, China; Wuhan, China; Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer.
Carosino CM, Olson DJ, Mazahreh RC, et al. · Mol Cancer Ther 2026
- PF-08046876, a differentiated integrin beta-6 antibody-drug conjugate delivering a potent camptothecin payload optimized for bystander effect and reduced drug efflux.
Mazahreh RC, Lim CB, Garcia NH, et al. · Mol Cancer Ther 2026
- First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
Peters S, Piha-Paul SA, Sehgal K, et al. · J Clin Oncol 2026
- Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?
Parisi C, Barlesi F, Planchard D · Cancer 2026
- Integrin beta-6: Its emerging role as a therapeutic target in solid tumors.
Sanborn RE, Peters S, Barbie D · Cancer Treat Rev 2026
- Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ࣙ50%: phase III study design.
Reck M, Lu S, O'Byrne KJ, et al. · Future Oncol 2025
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.